NASDAQ:CGEN Compugen (CGEN) Stock Price, News & Analysis $1.96 -0.01 (-0.51%) (As of 09/12/2024 ET) Add Compare Share Share Today's Range$1.95▼$2.0150-Day Range$1.56▼$2.1052-Week Range$0.53▼$3.03Volume139,886 shsAverage Volume453,172 shsMarket Capitalization$174.91 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Compugen alerts: Email Address Compugen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside104.1% Upside$4.00 Price TargetShort InterestHealthy1.83% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.07 to ($0.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.77 out of 5 starsMedical Sector644th out of 936 stocksBiological Products, Except Diagnostic Industry107th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingCompugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompugen has received no research coverage in the past 90 days.Read more about Compugen's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.83% of the outstanding shares of Compugen have been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Compugen has recently decreased by 5.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCompugen does not currently pay a dividend.Dividend GrowthCompugen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEN. Previous Next 2.8 News and Social Media Coverage News SentimentCompugen has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Compugen this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Compugen to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Compugen is held by insiders.Percentage Held by InstitutionsOnly 12.22% of the stock of Compugen is held by institutions.Read more about Compugen's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Compugen are expected to decrease in the coming year, from $0.07 to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compugen is -10.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compugen is -10.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompugen has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compugen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsBlacklisted by AI: Guilty Until Proven Innocent!AI has garnered a lot of attention post the launch of ChatGPT, and rightly so. But here's a chilling fact a lot of people don't know: For decades, agencies like the NSA have been using AI to illegally snoop into the private lives of millions of Americans.Watch this urgent video to find out how! About Compugen Stock (NASDAQ:CGEN)Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Read More CGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGEN Stock News HeadlinesSeptember 9 at 7:00 AM | prnewswire.comCompugen to Present at Single Cell Genomics 2024 ConferenceAugust 29, 2024 | prnewswire.comCompugen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 12, 2024 | Crypto 101 Media (Ad)The #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. August 27, 2024 | money.usnews.comCompugen LtdAugust 16, 2024 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Compugen (CGEN)August 13, 2024 | finance.yahoo.comCompugen Ltd. (CGEN)August 11, 2024 | finance.yahoo.comParty Time: Brokers Just Made Major Increases To Their Compugen Ltd. (NASDAQ:CGEN) Earnings ForecastsAugust 10, 2024 | seekingalpha.comCompugen Ltd. (CGEN) Q2 2024 Earnings Call TranscriptSeptember 12, 2024 | Crypto 101 Media (Ad)The #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. August 9, 2024 | markets.businessinsider.comCompugen: Strong Buy on Promising Trials, Strategic Alliances, and Solid FinancialsAugust 7, 2024 | finance.yahoo.comCompugen Ltd. (NASDAQ:CGEN): When Will It Breakeven?August 6, 2024 | prnewswire.comCompugen Reports Second Quarter 2024 ResultsAugust 6, 2024 | msn.comCompugen Q2 2024 Earnings PreviewJuly 31, 2024 | benzinga.comCheckpoint Therapeutics (NASDAQ:CKPT) Stock Quotes, Forecast and News SummaryJuly 29, 2024 | finanznachrichten.deCompugen Ltd.: Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid TumorsJuly 29, 2024 | prnewswire.comCompugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid TumorsJuly 23, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Compugen (CGEN)July 23, 2024 | prnewswire.comCompugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024See More Headlines Receive CGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/12/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGEN CUSIPN/A CIK1119774 Webwww.cgen.com Phone(723) 765-8585Fax972-3765-8555Employees70Year Founded1993Price Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+102.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.19) Trailing P/E RatioN/A Forward P/E Ratio28.29 P/E GrowthN/ANet Income$-18,750,000.00 Net MarginsN/A Pretax Margin-1.19% Return on Equity-16.10% Return on Assets-9.23% Debt Debt-to-Equity RatioN/A Current Ratio4.12 Quick Ratio4.12 Sales & Book Value Annual Sales$42.72 million Price / Sales4.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book2.71Miscellaneous Outstanding Shares89,240,000Free FloatN/AMarket Cap$176.70 million OptionableOptionable Beta2.65 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Anat Cohen-Dayag Ph.D. (Age 57)CEO, President & Director Comp: $796.52kDr. Zurit Levine Ph.D. (Age 56)Senior Vice President of Technology Innovation Comp: $345.7kDr. Pierre Ferre Ph.D. (Age 47)Vice President of Preclinical Development Comp: $415.1kMr. Alberto Sessa (Age 62)Chief Financial Officer Dr. Eran Ophir Ph.D. (Age 46)Chief Scientific Officer Ms. Yvonne NaughtonHead of Investor Relations & Corporate CommunicationsMr. Eran Ben DorGeneral Counsel & Corporate SecretaryMs. Dorit Amitay (Age 56)Vice President of Human Resources Dr. Yaron Turpaz M.B.A. (Age 53)Ph.D., Senior VP & Senior Advisor of Data and Informatics Solutions Rivka SchwartzVice President Research and DiscoveryMore ExecutivesKey CompetitorsCoherus BioSciencesNASDAQ:CHRSInhibrxNASDAQ:INBXTCR2 TherapeuticsNASDAQ:TCRRBlack Diamond TherapeuticsNASDAQ:BDTXC4 TherapeuticsNASDAQ:CCCCView All CompetitorsInstitutional OwnershipSquarepoint Ops LLCBought 16,253 shares on 8/14/2024Ownership: 0.099%Renaissance Technologies LLCSold 8,100 shares on 8/9/2024Ownership: 1.488%Rothschild Investment LLCBought 221,900 shares on 7/31/2024Ownership: 0.256%Taylor Frigon Capital Management LLCSold 7,298 shares on 7/29/2024Ownership: 0.000%ARK Investment Management LLCBought 48,979 shares on 7/26/2024Ownership: 0.000%View All Institutional Transactions CGEN Stock Analysis - Frequently Asked Questions How have CGEN shares performed this year? Compugen's stock was trading at $1.98 at the start of the year. Since then, CGEN shares have decreased by 1.0% and is now trading at $1.96. View the best growth stocks for 2024 here. How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) issued its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.06. The biotechnology company earned $6.70 million during the quarter, compared to analyst estimates of $2.68 million. What is Anat Cohen-Dayag's approval rating as Compugen's CEO? 2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Compugen's major shareholders? Compugen's top institutional investors include Taylor Frigon Capital Management LLC, Renaissance Technologies LLC (1.49%), ARK Investment Management LLC and Rothschild Investment LLC (0.26%). How do I buy shares of Compugen? Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV) and Inovio Pharmaceuticals (INO). This page (NASDAQ:CGEN) was last updated on 9/12/2024 by MarketBeat.com Staff From Our PartnersWhat Kamala WON’T Do if she wins the electionA lot of folks have their fingers crossed about Kamala Harris winning the election… After all, she’s promis...Banyan Hill Publishing | SponsoredInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGEN Stock Alerts